Kenvue Stock Plummets Amid Tylenol-Autism Report Fears

Market Shaken by Impending Health Report

Shares of Kenvue (NYSE: KVUE), the consumer health giant behind iconic brands like Tylenol and Band-Aid, experienced a significant downturn on Friday, September 5, 2025, plummeting by more than 10%. The sharp decline followed a report from The Wall Street Journal indicating that the U.S. Department of Health and Human Services (HHS) is preparing to release a study this month that could link the use of acetaminophen, the active ingredient in Tylenol, during pregnancy to an increased risk of autism in children.

The anticipated report, spearheaded by HHS Secretary Robert F. Kennedy Jr., has sent ripples through the financial markets and raised concerns among consumers. According to sources cited by the Journal, the HHS report will also propose that a medication derived from folate, a B vitamin, may be effective in treating symptoms of the developmental disorder in certain individuals. This development aligns with Secretary Kennedy’s stated mission to identify the causes of what he has termed the “autism epidemic” by September.

Kenvue and Regulatory Bodies Respond

In response to the news and the subsequent market reaction, Kenvue issued a strong rebuttal. The company, which was spun off from Johnson & Johnson in 2023, stands firmly by the safety of its flagship product. In a public statement, Kenvue affirmed its position, stating, “We have continuously evaluated the science and [continue] to believe there is no causal link between the use of acetaminophen during pregnancy and autism.”

Kenvue further noted that its assessment is supported by major health authorities. “The Food and Drug Administration and leading medical organizations agree on the safety of the drug, its use during pregnancy and the information provided on the Tylenol label,” the company added. This stance highlights the potential for a significant clash between the HHS under its current leadership and the established scientific consensus.

Navigating the Scientific Landscape

The controversy places a spotlight on the existing guidance from regulatory bodies. The U.S. Food and Drug Administration (FDA) currently states on its website that it has not found “clear evidence” that using acetaminophen appropriately during pregnancy leads to adverse developmental outcomes. However, the agency maintains a cautious position, advising pregnant women to consult with their healthcare providers before taking any over-the-counter medications.

Secretary Kennedy has previously challenged established medical science, particularly concerning vaccine policies and the use of mRNA technology. His focus on autism at the HHS has involved what he described in April as a “massive testing and research effort” aimed at determining the disorder’s root causes. The forthcoming report on Tylenol appears to be a direct result of this initiative, setting the stage for a contentious public health debate.

Implications for Consumers and the Company

The situation leaves Kenvue, the world’s largest pure-play consumer health company, in a precarious position. Tylenol is one of the most widely used pain relievers globally and a cornerstone of the company’s portfolio. Any official government report suggesting a link to autism, regardless of the broader scientific consensus, could have lasting effects on consumer trust and the product’s market share.

Investors and the public will be watching closely for the official release of the HHS report. The findings, and the scientific scrutiny that will inevitably follow, will be critical in shaping the future for both the Tylenol brand and its parent company, Kenvue. As reported by digitaltrendstoday.com, the financial markets have already priced in a significant level of risk, but the long-term impact remains to be seen.